Reviewer's report
Title:Acetaminophen-cysteine adducts during therapeutic dosing and following
overdose.
Version: 1Date:23 December 2010
Reviewer: James Dear
Reviewer's report:
The paper is further development of APAP-CYS adducts as clinical biomarkers.
The authors are to be congratulated on performing studies in therpeutic dosing -
a situation that is likely to confound clinical use of the marker.
I would like more discussion around the future for APAP-CYS adducts. For
example, do the authors see them having a role outwith the confirmation of
APAP ingestion in patients with an unknown cause for liver injury? Indeed, in
light of their current work could APAP-CYS even be used in this setting (as a
therapeutic dose of APAP leads to adduct formation)?
In the APAP overdose group there was a wide dynamic range of adducts. Do the
values correlate with other markers of liver injury (PT, reaching KCC, creatinine,
encephaolpathy etc?)
I suppose my key question for the authors is what added value do APAP-CYS
adducts provide over and above established markers?
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
'I declare that I have no competing interests
Reviewer's report
Title:Acetaminophen-cysteine adducts during therapeutic dosing and following
overdose.
Version: 1Date:23 December 2010
Reviewer: James Dear
Reviewer's report:
The paper is further development of APAP-CYS adducts as clinical biomarkers.
The authors are to be congratulated on performing studies in therpeutic dosing -
a situation that is likely to confound clinical use of the marker.
I would like more discussion around the future for APAP-CYS adducts. For
example, do the authors see them having a role outwith the confirmation of
APAP ingestion in patients with an unknown cause for liver injury? Indeed, in
light of their current work could APAP-CYS even be used in this setting (as a
therapeutic dose of APAP leads to adduct formation)?
In the APAP overdose group there was a wide dynamic range of adducts. Do the
values correlate with other markers of liver injury (PT, reaching KCC, creatinine,
encephaolpathy etc?)
I suppose my key question for the authors is what added value do APAP-CYS
adducts provide over and above established markers?
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
'I declare that I have no competing interests
Please review this paper.
user
Reviewer's report
Title:Acetaminophen-cysteine adducts during therapeutic dosing and following
overdose.
Version: 1Date:23 December 2010
Reviewer: James Dear
Reviewer's report:
The paper is further development of APAP-CYS adducts as clinical biomarkers.
The authors are to be congratulated on performing studies in therpeutic dosing -
a situation that is likely to confound clinical use of the marker.
I would like more discussion around the future for APAP-CYS adducts. For
example, do the authors see them having a role outwith the confirmation of
APAP ingestion in patients with an unknown cause for liver injury? Indeed, in
light of their current work could APAP-CYS even be used in this setting (as a
therapeutic dose of APAP leads to adduct formation)?
In the APAP overdose group there was a wide dynamic range of adducts. Do the
values correlate with other markers of liver injury (PT, reaching KCC, creatinine,
encephaolpathy etc?)
I suppose my key question for the authors is what added value do APAP-CYS
adducts provide over and above established markers?
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a
statistician.
Declaration of competing interests:
'I declare that I have no competing interests
assistant